National Wealth Management Group LLC Buys New Shares in GSK PLC Sponsored ADR $GSK

Key Points

• National Wealth Management Group LLC invested approximately $413,000 in GSK PLC Sponsored ADR by acquiring 10,656 shares in the first quarter.
• GSK recently reported quarterly earnings with an EPS of $1.23, exceeding analysts' estimates of $1.12, and had a revenue of $10.64 billion for the quarter.
• The company announced a quarterly dividend of $0.4206 per share, representing an annual yield of 4.3%, with a dividend payout ratio of 77.78%.

National Wealth Management Group LLC acquired a new stake in GSK PLC Sponsored ADR (NYSE:GSK - Free Report) during the first quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm acquired 10,656 shares of the pharmaceutical company's stock, valued at approximately $413,000.

A number of other hedge funds have also added to or reduced their stakes in the company. HHM Wealth Advisors LLC grew its stake in shares of GSK by 222.2% during the first quarter. HHM Wealth Advisors LLC now owns 667 shares of the pharmaceutical company's stock worth $26,000 after buying an additional 460 shares during the last quarter. Costello Asset Management INC bought a new stake in shares of GSK during the first quarter worth $31,000. Richardson Financial Services Inc. grew its stake in shares of GSK by 127.9% during the first quarter. Richardson Financial Services Inc. now owns 841 shares of the pharmaceutical company's stock worth $33,000 after buying an additional 472 shares during the last quarter. Olde Wealth Management LLC bought a new stake in shares of GSK during the first quarter worth $36,000. Finally, Cary Street Partners Investment Advisory LLC grew its stake in shares of GSK by 525.9% during the first quarter. Cary Street Partners Investment Advisory LLC now owns 1,014 shares of the pharmaceutical company's stock worth $39,000 after buying an additional 852 shares during the last quarter. 15.74% of the stock is owned by institutional investors.

Analyst Upgrades and Downgrades

A number of analysts have weighed in on GSK shares. Wall Street Zen raised shares of GSK from a "buy" rating to a "strong-buy" rating in a research note on Friday, September 5th. Berenberg Bank reaffirmed a "hold" rating on shares of GSK in a research note on Tuesday, June 3rd. Six analysts have rated the stock with a Hold rating and one has given a Sell rating to the company. According to MarketBeat, the stock presently has a consensus rating of "Reduce" and an average target price of $37.38.

GSK Trading Down 0.6%

Shares of NYSE:GSK traded down $0.27 during mid-day trading on Wednesday, reaching $40.52. 1,883,801 shares of the company's stock were exchanged, compared to its average volume of 5,081,247. The firm has a market capitalization of $82.52 billion, a price-to-earnings ratio of 18.76, a PEG ratio of 2.00 and a beta of 0.53. The business's fifty day moving average price is $38.59 and its 200-day moving average price is $38.40. The company has a debt-to-equity ratio of 1.07, a quick ratio of 0.57 and a current ratio of 0.87. GSK PLC Sponsored ADR has a twelve month low of $31.72 and a twelve month high of $44.03.

GSK (NYSE:GSK - Get Free Report) last issued its quarterly earnings results on Wednesday, July 30th. The pharmaceutical company reported $1.23 EPS for the quarter, topping analysts' consensus estimates of $1.12 by $0.11. The company had revenue of $10.64 billion for the quarter, compared to analyst estimates of $7.92 billion. GSK had a net margin of 10.81% and a return on equity of 49.22%. GSK's revenue was up 1.3% compared to the same quarter last year. During the same quarter in the previous year, the business earned $0.43 earnings per share. GSK has set its FY 2025 guidance at 4.590-4.590 EPS. On average, research analysts predict that GSK PLC Sponsored ADR will post 4.14 EPS for the current fiscal year.

GSK Cuts Dividend

The company also recently announced a quarterly dividend, which will be paid on Thursday, October 9th. Investors of record on Friday, August 15th will be issued a $0.4206 dividend. The ex-dividend date is Friday, August 15th. This represents a $1.68 annualized dividend and a yield of 4.2%. GSK's payout ratio is presently 77.78%.

GSK Profile

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D.